Patents by Inventor Johnathan Alexander McLean
Johnathan Alexander McLean has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11970485Abstract: Disclosed herein are compounds of formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.Type: GrantFiled: October 19, 2022Date of Patent: April 30, 2024Assignee: ELI LILLY AND COMPANYInventors: Gabrielle R. Kolakowski, Erin D. Anderson, Steven W. Andrews, Christopher Pierre Albert Jean Boldron, Kevin R. Condroski, Thomas C. Irvin, Manoj Kumar, Elizabeth A. McFaddin, Megan L. McKenney, Johnathan Alexander McLean, Tiphaine Mouret, Michael J. Munchhof, Thomas Pierre Dino Pancaldi, Michael Alexander Pilkington-Miksa, Marta Pinto
-
Patent number: 11878970Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.Type: GrantFiled: May 26, 2022Date of Patent: January 23, 2024Assignee: PETRA PHARMA CORPORATIONInventors: Erin Danielle Anderson, Sean Douglas Aronow, Nicholas A. Boyles, Xiaohong Chen, Surendra Dawadi, Eugene R. Hickey, Thomas Combs Irvin, Edward A. Kesicki, Gabrielle R. Kolakowski, Jennifer Lynn Knight, Manoj Kumar, Katelyn Frances Long, Christopher Glenn Mayne, Johnathan Alexander McLean, Gerit Maria Pototschnig, Hua-Yu Wang, Michael Brian Welch, Tien Widjaja
-
Publication number: 20230286960Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, W, X, Y, s, and Ring A are as described herein.Type: ApplicationFiled: April 18, 2023Publication date: September 14, 2023Inventors: Erin Danielle ANDERSON, Sean Douglas ARONOW, Nicholas A. BOYLES, Markus K. DAHLGREN, Shulu FENG, Aleksey I. GERASYUTO, Eugene R. HICKEY, Thomas Combs IRVIN, Edward A. KESICKI, Anke KLIPPEL-GIESE, Jennifer Lynn KNIGHT, Gabrielle R. KOLAKOWSKI, Manoj KUMAR, Katelyn Frances LONG, Christopher Glenn MAYNE, David L. MCELLIGOTT, Johnathan Alexander MCLEAN, Loredana PUCA, Kannan Karukurichi RAVI, Daniel Lee SEVERANCE, Michael Brian WELCH, Tien WIDJAJA
-
Publication number: 20230265085Abstract: Disclosed herein are compounds of formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.Type: ApplicationFiled: October 19, 2022Publication date: August 24, 2023Inventors: Gabrielle R. KOLAKOWSKI, Erin D. ANDERSON, Steven W. ANDREWS, Christopher Pierre Albert Jean BOLDRON, Kevin R. CONDROSKI, Thomas C. IRVIN, Manoj KUMAR, Elizabeth A. MCFADDIN, Megan L. MCKENNEY, Johnathan Alexander MCLEAN, Tiphaine MOURET, Michael J. MUNCHHOF, Thomas Pierre Dino PANCALDI, Michael Alexander PILKINGTON-MIKSA, Marta PINTO
-
Patent number: 11697647Abstract: Disclosed herein are compounds of formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.Type: GrantFiled: November 5, 2021Date of Patent: July 11, 2023Assignee: Eli Lilly and CompanyInventors: Gabrielle R. Kolakowski, Erin D. Anderson, Steven W. Andrews, Christopher Pierre Albert Jean Boldron, Kevin R. Condroski, Thomas C. Irvin, Manoj Kumar, Elizabeth A. McFaddin, Megan L. McKenney, Johnathan Alexander McLean, Tiphaine Mouret, Michael J. Munchhof, Thomas Pierre Dino Pancaldi, Michael Alexander Pilkington-Miksa, Marta Pinto
-
Patent number: 11649227Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, W, X, Y, s, and Ring A are as described herein.Type: GrantFiled: April 2, 2021Date of Patent: May 16, 2023Assignee: Petra Pharma CorporationInventors: Erin Danielle Anderson, Sean Douglas Aronow, Nicholas A. Boyles, Markus K. Dahlgren, Shulu Feng, Aleksey I. Gerasyuto, Eugene R. Hickey, Thomas Combs Irvin, Edward A. Kesicki, Anke Klippel-Giese, Jennifer Lynn Knight, Gabrielle R. Kolakowski, Manoj Kumar, Katelyn Frances Long, Christopher Glenn Mayne, David L. McElligott, Johnathan Alexander McLean, Loredana Puca, Kannan Karukurichi Ravi, Daniel Lee Severance, Michael Brian Welch, Tien Widjaja
-
Publication number: 20230096175Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: May 26, 2022Publication date: March 30, 2023Inventors: Erin Danielle ANDERSON, Sean Douglas ARONOW, Nicholas A. BOYLES, Xiaohong CHEN, Surendra DAWADI, Eugene R. HICKEY, Thomas Combs IRVIN, Edward A. KESICKI, Gabrielle R. KOLAKOWSKI, Jennifer Lynn KNIGHT, Manoj KUMAR, Katelyn Frances LONG, Christopher Glenn MAYNE, Johnathan Alexander MCLEAN, Gerit Maria POTOTSCHNIG, Hua-Yu WANG, Michael Brian WELCH, Tien WIDJAJA
-
Publication number: 20220372023Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, W, X, Y, s, and Ring A are as described herein.Type: ApplicationFiled: April 2, 2021Publication date: November 24, 2022Inventors: Erin Danielle ANDERSON, Sean Douglas ARONOW, Nicholas A. BOYLES, Markus K. DAHLGREN, Shulu FENG, Aleksey I. GERASYUTO, Eugene R. HICKEY, Thomas Combs IRVIN, Edward A. KESICKI, Anke KLIPPEL-GIESE, Jennifer Lynn KNIGHT, Gabrielle R. KOLAKOWSKI, Manoj KUMAR, Katelyn Frances LONG, Christopher Glenn MAYNE, David L. MCELLIGOTT, Johnathan Alexander MCLEAN, Loredana PUCA, Kannan Karukurichi RAVI, Daniel Lee SEVERANCE, Michael Brian WELCH, Tien WIDJAJA
-
Publication number: 20220144816Abstract: Disclosed herein are compounds of formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.Type: ApplicationFiled: November 5, 2021Publication date: May 12, 2022Inventors: Gabrielle R. Kolakowski, Erin D. ANDERSON, Steven W. Andrews, Christopher Pierre Albert Jean BOLDON, Kevin R. CONDROSKI, Thomas C. IRVIN, Manoj KUMAR, Elizabeth A. MCFADDIN, Megan L. MCKENNEY, Johnathan Alexander MCLEAN, Tiphaine MOURET, Michael J. MUNCHHOF, Thomas Pierre Dino PANCALDI, Michael Alexander PILKINGTON-MIKSA, Marta PINTO
-
Patent number: 9879029Abstract: The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.Type: GrantFiled: December 15, 2015Date of Patent: January 30, 2018Assignee: Eli Lilly and CompanyInventors: Guillermo S. Cortez, Sajan Joseph, Johnathan Alexander McLean, William Thomas McMillen, Michael John Rodriguez, Gaiying Zhao
-
Publication number: 20170267691Abstract: The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.Type: ApplicationFiled: December 15, 2015Publication date: September 21, 2017Inventors: Guillermo S. Cortez, Sajan Joseph, Johnathan Alexander McLean, William Thomas McMillen, Michael John Rodriguez, Gaiying Zhao
-
Patent number: 9469652Abstract: The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.Type: GrantFiled: December 16, 2015Date of Patent: October 18, 2016Assignee: Eli Lilly and CompanyInventors: Guillermo S. Cortez, Sajan Joseph, Johnathan Alexander McLean, William T. McMillen, Michael John Rodriguez, Gaiying Zhao
-
Publication number: 20160176896Abstract: The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.Type: ApplicationFiled: December 16, 2015Publication date: June 23, 2016Inventors: Guillermo S. Cortez, Sajan Joseph, Johnathan Alexander McLean, William T. McMillen, Michael John Rodriguez, Gaiying Zhao
-
Publication number: 20110294792Abstract: The present invention provides kinase inhibitors of Formula I.Type: ApplicationFiled: August 9, 2011Publication date: December 1, 2011Applicant: ELI LILLY AND COMPANYInventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel, Brian Raymond Berridge, Charles Edward Ruegg, John Morris Sullivan
-
Patent number: 8058425Abstract: The present invention provides kinase inhibitors of Formula I.Type: GrantFiled: May 4, 2011Date of Patent: November 15, 2011Assignee: Eli Lilly and CompanyInventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel, Brian Raymond Berridge, Charles Edward Ruegg, John Morris Sullivan
-
Publication number: 20110207721Abstract: The present invention provides kinase inhibitors of Formula I.Type: ApplicationFiled: May 4, 2011Publication date: August 25, 2011Applicant: ELI LILLY AND COMPANYInventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel, Brian Raymond Berridge, Charles Edward Ruegg, John Morris Sullivan
-
Patent number: 7666879Abstract: The present invention provides compounds that are inhibitors of VEGF-R2 of the formula: (I) and methods of using these compounds.Type: GrantFiled: February 23, 2006Date of Patent: February 23, 2010Assignee: Eli Lilly and CompanyInventors: David Anthony Barda, Timothy Paul Burkholder, Joshua Ryan Clayton, Yan Hao, James Robert Henry, John Monte Knobeloch, Johnathan Alexander McLean, David Mendel, Mark Edward Rempala, Zhao-Qing Wang, Yvonne Yee Mai Yip, Boyu Zhong
-
Publication number: 20090227622Abstract: The present invention provides compounds that are inhibitors of VEGF-R2 of the formula: (I) and methods of using these compounds.Type: ApplicationFiled: February 23, 2006Publication date: September 10, 2009Inventors: David Anthony Barda, Timothy Paul Burkholder, Joshua Ryan Clayton, Yan Hao, James Robert Henry, John Monte Knobeloch, Johnathan Alexander Mclean, David Mendel, Mark Edward Rempala, Zhao-Qing Wang, Yvonne Yee Yip, Boyu Zhong
-
Publication number: 20090105229Abstract: The present invention provides kinase inhibitors of Formula I.Type: ApplicationFiled: December 12, 2008Publication date: April 23, 2009Inventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel
-
Patent number: RE48635Abstract: The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.Type: GrantFiled: May 22, 2019Date of Patent: July 13, 2021Assignee: Eli Lilly and CompanyInventors: Guillermo S. Cortez, Sajan Joseph, Johnathan Alexander McLean, William T. McMillen, Michael John Rodriguez, Gaiying Zhao